Advertisement

Tumor Biology

, Volume 36, Issue 4, pp 2421–2426 | Cite as

Distinct prognostic values of ALDH1 isoenzymes in breast cancer

  • Shaokun Wu
  • Weiping Xue
  • Xiaobo Huang
  • Xiaoli Yu
  • Ming Luo
  • Ying Huang
  • Yimin Liu
  • Zhuofei Bi
  • Xingsheng Qiu
  • Shoumin Bai
Research Article

Abstract

Aldehyde dehydrogenase 1 (ALDH1), also known as aldehyde dehydrogenase 1 family, is composed of six enzymes that are expressed at high levels in stem cells and are involved in the regulation of stem cell function. Increased ALDH1 activity has been found in the stem cell populations of leukemia and some solid tumors including breast cancer (BC). However, which ALDH1’s isoenzymes are contributing to ALDH1 activity has not been determined. In addition, the prognostic value of individual ALDH1 isoenzyme is not clear. In the current study, we investigated the prognostic value of ALDH1 isoenzymes in BC patients through “the Kaplan-Meier plotter” (KM plotter) database, in which updated gene expression data and survival information are from a total of 3455 BC patients. ALDH1A1 messenger RNA (mRNA) high expression was found to be correlated to worsen overall survival (OS) for all BC patients. ALDH1A2 and ALDH1L1 mRNA high expressions were found to be correlated to better OS for all BC patients. Both of ALDH1A3 and ALDH1B1 mRNA high expressions were not found to be correlated to OS for all BC patients. These results strongly support that ALDH1A1 was only a biomarker for predicting poor survival of BC patients among ALDH1 isoenzymes. ALDH1A1 might be a major contributor of ALDH1 activity in BC, since only ALDH1A1 mRNA high expression was found to be significantly correlated to worsen OS for all BC patients.

Keywords

Breast cancer Cancer stem cell ALDH1 Prognosis KM plotter 

Notes

Conflicts of interest

None

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274:113–26.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Coleman RE, Gregory W, Marshall H, Wilson C, Holen I. The metastatic microenvironment of breast cancer: clinical implications. Breast. 2013;22 Suppl 2:S50–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Pang LY, Argyle DJ. Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. Biochim Biophys Acta. 2009;1792:380–91.CrossRefPubMedGoogle Scholar
  5. 5.
    Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol. 2008;26:2813–20.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–61.CrossRefPubMedGoogle Scholar
  7. 7.
    Clarke MF. Self-renewal and solid-tumor stem cells. Biol Blood Marrow Transplant. 2005;11:14–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev. 2009;18:17–25.CrossRefPubMedGoogle Scholar
  10. 10.
    Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 2011;7:292–306.CrossRefPubMedGoogle Scholar
  11. 11.
    Ehlers CL. Variations in ADH and ALDH in Southwest California Indians. Alcohol Res Health. 2007;30:14–7.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Vasiliou V, Thompson DC, Smith C, Fujita M, Chen Y. Aldehyde dehydrogenases: from eye crystallins to metabolic disease and cancer stem cells. Chem Biol Interact. 2013;202:2–10.CrossRefPubMedGoogle Scholar
  13. 13.
    Muzio G, Maggiora M, Paiuzzi E, Oraldi M, Canuto RA. Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med. 2012;52:735–46.CrossRefPubMedGoogle Scholar
  14. 14.
    Gaur P, Sceusi EL, Samuel S, et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011;141:1728–37.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Owens BM, Zhu YX, Suen TC, et al. Specific homeodomain-DNA interactions are required for HOX11-mediated transformation. Blood. 2003;101:4966–74.CrossRefPubMedGoogle Scholar
  16. 16.
    Kim YS, Jung MJ, Ryu DW, Lee CH. Clinicopathologic characteristics of breast cancer stem cells identified on the basis of aldehyde dehydrogenase 1 expression. J Breast Cancer. 2014;17:121–8.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kang EJ, Jung H, Woo OH, et al. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer. Neoplasma. 2014;61:352–62.CrossRefPubMedGoogle Scholar
  18. 18.
    Zhong Y, Shen S, Zhou Y, et al. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype. Med Oncol. 2014;31:864.CrossRefPubMedGoogle Scholar
  19. 19.
    Charafe-Jauffret E, Ginestier C, Bertucci F, et al. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res. 2013;73:7290–300.CrossRefPubMedGoogle Scholar
  20. 20.
    Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010;16:45–55.CrossRefPubMedGoogle Scholar
  21. 21.
    Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555–67.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–31.CrossRefPubMedGoogle Scholar
  23. 23.
    Gyorffy B, Benke Z, Lanczky A, et al. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat. 2012;132:1025–34.CrossRefPubMedGoogle Scholar
  24. 24.
    Liu M, Wang G, Gomez-Fernandez CR, Guo S. GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancer. Plos One. 2012;7:e46410.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Tilghman SL, Townley I, Zhong Q, et al. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics. 2013;12:2440–55.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Zhou C, Zhong Q, Rhodes LV, et al. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res. 2012;14:R45.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Maciejczyk A, Szelachowska J, Czapiga B, et al. Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis. J Histochem Cytochem. 2013;61:330–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Maciejczyk A, Lacko A, Ekiert M, et al. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients. Histol Histopathol. 2013;28:513–24.PubMedGoogle Scholar
  29. 29.
    Maciejczyk A, Jagoda E, Wysocka T, et al. ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome. Pathol Oncol Res. 2012;18:331–42.CrossRefPubMedGoogle Scholar
  30. 30.
    Adam MA. New prognostic factors in breast cancer. Adv Clin Exp Med. 2013;22:5–15.Google Scholar
  31. 31.
    Vasiliou V, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact. 2000;129:1–19.CrossRefPubMedGoogle Scholar
  32. 32.
    Ginestier C, Wicinski J, Cervera N, et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle. 2009;8:3297–302.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Burger PE, Gupta R, Xiong X, et al. High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells. Stem Cells. 2009;27:2220–8.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Chute JP, Muramoto GG, Whitesides J, et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A. 2006;103:11707–12.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Krupenko NI, Dubard ME, Strickland KC, Moxley KM, Oleinik NV, Krupenko SA. ALDH1L2 is the mitochondrial homolog of 10-formyltetrahydrofolate dehydrogenase. J Biol Chem. 2010;285:23056–63.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Xu SL, Zeng DZ, Dong WG, et al. Distinct patterns of ALDH1A1 expression predict metastasis and poor outcome of colorectal carcinoma. Int J Clin Exp Pathol. 2014;7:2976–86.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Yang L, Ren Y, Yu X, et al. ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma. Mod Pathol. 2014;27:775–83.CrossRefPubMedGoogle Scholar
  38. 38.
    Wang K, Chen X, Zhan Y, et al. Increased expression of ALDH1A1 protein is associated with poor prognosis in clear cell renal cell carcinoma. Med Oncol. 2013;30:574.CrossRefPubMedGoogle Scholar
  39. 39.
    Li XS, Xu Q, Fu XY, Luo WS. ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer. BMC Cancer. 2014;14:705.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Xu J, Muller S, Nannapaneni S, et al. Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer. Eur J Cancer. 2012;48:1682–91.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Keymoosi H, Gheytanchi E, Asgari M, Shariftabrizi A, Madjd Z. ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder. Asian Pac J Cancer Prev. 2014;15:2013–20.CrossRefPubMedGoogle Scholar
  42. 42.
    Mieog JS, de Kruijf EM, Bastiaannet E, et al. Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer. BMC Cancer. 2012;12:42.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol. 2010;176:2131–8.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Liu Y, Lv DL, Duan JJ, et al. ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis. BMC Cancer. 2014;14:444.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Shaokun Wu
    • 1
  • Weiping Xue
    • 1
  • Xiaobo Huang
    • 2
  • Xiaoli Yu
    • 1
  • Ming Luo
    • 1
  • Ying Huang
    • 2
  • Yimin Liu
    • 1
  • Zhuofei Bi
    • 1
  • Xingsheng Qiu
    • 1
  • Shoumin Bai
    • 1
  1. 1.Department of Oncology, SunYat-Sen Memorial HospitalSunYat-Sen UniversityGuangzhouChina
  2. 2.Department of RadiotherapySun Yat-Sen University Cancer CenterGuangdongChina

Personalised recommendations